Physician profile
Jay S Hwang
NPI 1386644268
$4,322.92
in general payments reported to CMS, 2019-2025
26 companies · $754 in 2025
The $754 reported for 2025 was more than what a typical Urology provider received nationally (typical 2025 total: $631).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,798 · 2020: $407 · 2021: $271 · 2022: $129 · 2023: $848 · 2024: $116 · 2025: $754.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,261 · Travel and Lodging: $457.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,260.77 |
| Travel and Lodging | $457.46 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $978.93 | 2019-2025 | Rezum Generator, Moses 550 D\F\L, Axonics |
| Teleflex LLC | $761.94 | 2019-2025 | Urolift |
| Intuitive Surgical, INC. | $497.63 | 2019 | |
| Healthtronics Stone Solutions, LLC | $370.11 | 2021-2025 | Dornier Medtech, Dornier Medtech, Cvac Aspiration System |
| Astellas Pharma US INC | $301.71 | 2019-2025 | Xtandi, Myrbetriq |
| Neotract INC. | $217.80 | 2019 | |
| Amgen INC. | $183.92 | 2019-2020 | |
| Duchesnay USA Incorporated | $177.62 | 2019 | |
| Olympus America INC. | $142.41 | 2019-2020 | |
| Janssen Biotech, INC. | $138.13 | 2019-2020 | |
| Antares Pharma, INC. | $105.98 | 2019-2024 | Xyosted |
| Endo USA, INC. | $64.51 | 2025 | Xiaflex, Aveed |
| Abbvie INC. | $52.02 | 2019-2020 | |
| Dendreon Pharmaceuticals LLC | $46.30 | 2019-2020 | |
| Sumitomo Pharma America, INC. | $44.95 | 2023-2024 | Orgovyx, Gemtesa |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Coopersurgical, INC. | $32.80 | 2019 | |
| Procept Biorobotics Corporation | $29.60 | 2025 | |
| Myriad Genetic Laboratories, INC. | $29.42 | 2024-2025 | Prolaris |
| Merck Sharp & Dohme LLC | $27.44 | 2024 | Keytruda |
| Profound Medical Corp. | $26.93 | 2025 | Tulsa-Pro |
| Novartis Pharmaceuticals Corporation | $20.25 | 2025 | |
| Laborie Medical Technologies Corp. | $16.47 | 2023 | |
| Endo Pharmaceuticals INC. | $16.08 | 2023 | Xiaflex, Aveed |
| Aytu Biopharma, INC. | $13.71 | 2020 | |
| Tolmar, INC. | $13.62 | 2025 | Jatenzo, Eligard |
| Bayer Healthcare Pharmaceuticals INC. | $12.64 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jay Hwang listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.